THRM Stock Analysis: Gentherm | NASDAQ

Seat Heaters, Climate Control, Battery Management, Patient Warming

Total Rating 58

Safety 87

Buy Signal 0.47

Auto Parts
Industry Rotation: +6.7

Market Cap: 1.19B
Avg Turnover: 11.5M

Risk 3d forecast

Volatility38.2%

VaR 5^th Pctl5.92%

VaR vs Median-5.35%

Reward TTM

Sharpe Ratio0.39

Rel. Str. IBD65.6

Rel. Str. Peer Group75.7

Character TTM

Beta1.132

Beta Downside1.399

Hurst Exponent0.438

Drawdowns 3y

Max DD60.59%

CAGR/Max DD-0.18

CAGR/Mean DD-0.34

EPS (Earnings per Share)

EPS CAGR: -1.66%
EPS Trend: -11.8%

Last SUE: 0.77
Qual. Beats: 0

Revenue

Rev. CAGR: 2.06%
Rev. Trend: 71.8%

Last SUE: 2.87
Qual. Beats: 3

Warnings

Below Avwap Earnings

Tailwinds

Confidence

Seasonality 11.6 years of data

Jan -0.3% 7

Feb -2.3% 8

Mar -5.6% 9

Apr -0.6% 5

May +3.0% 34

Jun -2.5% 8

Jul +7.2% 37

Aug -0.4% 13

Sep -7.0% 52

Oct -6.6% 16

Nov +8.1% 53

Dec +1.9% 27

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: THRM Gentherm

Gentherm Incorporated (NASDAQ: THRM) is a U.S.-based manufacturer specializing in thermal management and pneumatic comfort technologies, operating across two segments: Automotive and Medical. The Automotive segment supplies climate comfort systems (seat heaters, blowers, thermoelectric devices, steering wheel heaters), pneumatic lumbar and massage solutions, automotive cable and battery performance technologies, valve systems, and electronic control units, serving light vehicle original equipment manufacturers (OEMs) and Tier 1 suppliers globally. The Medical segment provides patient temperature management systems under the Blanketrol and Astotherm brands for hyper-hypothermia therapy, surgical normothermia, and warming/cooling applications. The company, originally incorporated in 1991 as Amerigon and renamed Gentherm in 2012, is headquartered in Northville, Michigan, and operates manufacturing and sales operations in more than ten countries, including the United States, China, Germany, and Mexico.

As an Automotive Parts & Equipment company within the Consumer Discretionary sector, Gentherms business is closely tied to global light vehicle production volumes, making its revenue sensitive to automotive cyclicality. The Medical segment, while smaller, provides diversification into the relatively more stable medical device industry.

Headlines to Watch Out For

EV battery thermal management drives automotive revenue growth
Medical segment margins expand as surgical procedure volumes recover
European and Chinese auto production cuts pressure seat heater volumes

Piotroski VR-10 (Strict) 4.5

Net Income: 26.6m TTM > 0 and > 6% of Revenue
FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.74 > 1.0
NWC/Revenue: 28.80% < 20% (prev 26.28%; Δ 2.52% < -1%)
CFO/TA 0.06 > 3% & CFO 87.4m > Net Income 26.6m
Net Debt (163.7m) to EBITDA (114.5m): 1.43 < 3
Current Ratio: 2.06 > 1.5 & < 3
Outstanding Shares: last quarter (31.1m) vs 12m ago 1.31% < -2%
Gross Margin: 23.43% > 18% (prev 24.58%; Δ -1.15% > 0.5%)
Asset Turnover: 110.4% > 50% (prev 106.8%; Δ 3.63% > 0%)
Interest Coverage Ratio: 4.71 > 6 (EBIT TTM 58.6m / Interest Expense TTM 12.4m)

Altman Z'' 4.83

A: 0.30 (Total Current Assets 880.0m - Total Current Liabilities 426.3m) / Total Assets 1.49b
B: 0.48 (Retained Earnings 722.7m / Total Assets 1.49b)
C: 0.04 (EBIT TTM 58.6m / Avg Total Assets 1.43b)
D: 0.94 (Book Value of Equity 723.1m / Total Liabilities 770.1m)
Altman-Z'' = 4.83 = AA

Beneish M -2.92

DSRI: 1.03 (Receivables 370.5m/330.5m, Revenue 1.58b/1.45b)
GMI: 1.05 (GM 24.58% / 23.43%)
AQI: 0.95 (AQ_t 0.20 / AQ_t-1 0.21)
SGI: 1.08 (Revenue 1.58b / 1.45b)
TATA: -0.04 (NI 26.6m - CFO 87.4m) / TA 1.49b)
Beneish M = -2.92 (Cap -4..+1) = A

What is the price of THRM shares?

As of September 08, 2026, the stock is trading at USD 40.70 with a total of 240,759 shares traded. Over the past week, the price has changed by +2.92%, over one month by -1.36%, over three months by +10.69% and over the past year by +11.17%.

Current recommended Stop Loss: 38.60 (which is 5.2% or 1.4 ATR below the current price).

Is THRM a buy, sell or hold?

Gentherm has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy THRM.

StrongBuy: 5
Buy: 0
Hold: 3
Sell: 0
StrongSell: 0

What are the forecasts/targets for the THRM price?

Analysts Target Price	47.7	17.2%

Gentherm (THRM) - Fundamental Data Overview as of 03 September 2026

Market Cap USD = 1.19b (1.19b USD * 1.0 USD.USD)
P/E Trailing = 44.907
P/E Forward = 14.2857
P/S = 0.7508
P/B = 1.6683
P/EG = 1.0175
Revenue TTM = 1.58b USD
EBIT TTM = 58.6m USD
EBITDA TTM = 114.5m USD
Long Term Debt = 272.4m USD (from longTermDebt, last quarter)
Short Term Debt = 9.07m USD (from shortTermDebt, last quarter)
Debt = 376.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 51.8m
Net Debt = 163.7m USD (calculated: Debt 376.9m - CCE 213.2m)
Enterprise Value = 1.35b USD (1.19b + Debt 376.9m - CCE 213.2m)
Interest Coverage Ratio = 4.71 (Ebit TTM 58.6m / Interest Expense TTM 12.4m)
EV/FCF = 33.01x (Enterprise Value 1.35b / FCF TTM 40.9m)
FCF Yield = 3.03% (FCF TTM 40.9m / Enterprise Value 1.35b)
FCF Margin = 2.60% (FCF TTM 40.9m / Revenue TTM 1.58b)
Net Margin = 1.69% (Net Income TTM 26.6m / Revenue TTM 1.58b)
Gross Margin = 23.43% ((Revenue TTM 1.58b - Cost of Revenue TTM 1.21b) / Revenue TTM)
Gross Margin QoQ = 23.17% (prev 24.70%)
Tobins Q-Ratio = 0.90 (Enterprise Value 1.35b / Total Assets 1.49b)
Interest Expense / Debt = 3.30% (Interest Expense 12.4m / Debt 376.9m)
Taxrate = 42.42% (19.6m / 46.2m)
NOPAT = 33.7m (EBIT 58.6m * (1 - 42.42%))
Current Ratio = 2.06 (Total Current Assets 880.0m / Total Current Liabilities 426.3m)
Debt / Equity = 0.52 (Debt 376.9m / totalStockholderEquity, last quarter 723.1m)
Debt / EBITDA = 1.43 (Net Debt 163.7m / EBITDA 114.5m)
Debt / FCF = 4.00 (Net Debt 163.7m / FCF TTM 40.9m)
Total Stockholder Equity = 719.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.86% (Net Income 26.6m / Total Assets 1.49b)
RoE = 3.69% (Net Income TTM 26.6m / Total Stockholder Equity 719.5m)
RoCE = 5.91% (EBIT 58.6m / Capital Employed (Equity 719.5m + L.T.Debt 272.4m))
RoIC = 3.38% (NOPAT 33.7m / Invested Capital 997.2m)
WACC = 8.02% (E(1.19b)/V(1.56b) * Re(9.97%) + D(376.9m)/V(1.56b) * Rd(3.30%) * (1-Tc(0.42)))
Discount Rate = 9.97% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -73.52 | Cagr: -0.90%
[DCF] Terminal Value 73.34% ; FCFF base≈43.5m ; Y1≈38.6m ; Y5≈32.1m
[DCF] Fair Price = 11.37 (EV 512.7m - Net Debt 163.7m = Equity 349.0m / Shares 30.7m; r=8.35% [WACC [floored]]; 5y FCF grow -13.64% → 2.50% )
EPS Correlation: -11.84 | EPS CAGR: -1.66% | SUE: 0.77 | # QB: 0
Revenue Correlation: 71.79 | Revenue CAGR: 2.06% | SUE: 2.87 | # QB: 3
EPS current Quarter (2026-09-30): EPS=0.66 | Chg30d=+3.71% | Revisions=-12% | Analysts=5
EPS current Year (2026-12-31): EPS=2.92 | Chg30d=+7.44% | Revisions=+67% | GrowthEPS=+28.6% | GrowthRev=+8.7%
EPS next Year (2027-12-31): EPS=3.28 | Chg30d=+6.13% | Revisions=+62% | GrowthEPS=+12.2% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: +53% (up=13, down=3)